Admin
On Oct. 7, California Governor Gavin Newsom vetoed Senate Bill 58 (SB 58), which would’ve decriminalized the use of natural psychedelics such as psilocybin mushrooms and ayahuasca for adults aged 21 and over.
Newsom said that while he supports “new opportunities to address mental health through psychedelic medicines,” the state needs to establish regulations before legalization.
“California should immediately begin work to set up regulated treatment guidelines – replete with dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments and medical clearance of no underlying psychoses,” Newsom said in a statement.
One of major proponents of SB 58 is Dr. Bronner’s (Vista, CA), manufacturer of the top-selling natural soap brand in North America. The company condemned the veto but remains hopeful that the legislation will pass.
“Although the veto of SB 58 is a major disappointment to our coalition and a setback for all who are committed to criminal justice and mental health reform, Gov. Newsom’s veto message shows there is still a path forward,” said David Bronner, the cosmic engagement officer of Dr. Bronner’s.
According to Dr. Bronner’s, psychedelic therapy has shown “great promise” in studies and trials from Johns Hopkins University, New York University and the University of California, Los Angeles. Psychedelics are also being tested for substance-use disorders and chronic pain.
Psilocybin was recently approved in Canada for terminally ill patients and end-of-life anxiety, the company stated.
In 2017 and 2018, the Food and Drug Administration (FDA) granted “breakthrough status” for MDMA on PTSD and psilocybin on depression. Breakthrough status means these therapies may provide substantial improve over the currently available options, Dr. Bronner’s said.
Dr. Bronner’s has long supported the use of psychedelics medicines. In addition to lobbying efforts, Dr. Bronner’s donated millions of dollars to policy reforms over the last decade, the company said.
“Our world is grappling with epidemics of depression, anxiety, PTSD and addiction that millions suffer from,” Bronner said. “Natural psychedelic medicines used responsibly are life-saving medicines that the world needs now, especially traumatized populations such as veterans and [BIPOC] communities.”
SB 58 was a bipartisan effort led by California Senator Scott Wiener (D-San Francisco) and a coalition of advocates for psychedelic therapy, criminal justice and mental health reform, including Dr. Bronner’s.
On Oct. 7, California Governor Gavin Newsom vetoed Senate Bill 58 (SB 58), which would’ve decriminalized the use of natural psychedelics such as psilocybin mushrooms and ayahuasca for adults aged 21 and over.
Newsom said that while he supports “new opportunities to address mental health through psychedelic medicines,” the state needs to establish regulations before legalization.
“California should immediately begin work to set up regulated treatment guidelines – replete with dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments and medical clearance of no underlying psychoses,” Newsom said in a statement.
One of major proponents of SB 58 is Dr. Bronner’s (Vista, CA), manufacturer of the top-selling natural soap brand in North America. The company condemned the veto but remains hopeful that the legislation will pass.
“Although the veto of SB 58 is a major disappointment to our coalition and a setback for all who are committed to criminal justice and mental health reform, Gov. Newsom’s veto message shows there is still a path forward,” said David Bronner, the cosmic engagement officer of Dr. Bronner’s.
According to Dr. Bronner’s, psychedelic therapy has shown “great promise” in studies and trials from Johns Hopkins University, New York University and the University of California, Los Angeles. Psychedelics are also being tested for substance-use disorders and chronic pain.
Psilocybin was recently approved in Canada for terminally ill patients and end-of-life anxiety, the company stated.
In 2017 and 2018, the Food and Drug Administration (FDA) granted “breakthrough status” for MDMA on PTSD and psilocybin on depression. Breakthrough status means these therapies may provide substantial improve over the currently available options, Dr. Bronner’s said.
Dr. Bronner’s has long supported the use of psychedelics medicines. In addition to lobbying efforts, Dr. Bronner’s donated millions of dollars to policy reforms over the last decade, the company said.
“Our world is grappling with epidemics of depression, anxiety, PTSD and addiction that millions suffer from,” Bronner said. “Natural psychedelic medicines used responsibly are life-saving medicines that the world needs now, especially traumatized populations such as veterans and [BIPOC] communities.”
SB 58 was a bipartisan effort led by California Senator Scott Wiener (D-San Francisco) and a coalition of advocates for psychedelic therapy, criminal justice and mental health reform, including Dr. Bronner’s.
